Clinical Trial Update: Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing capmatinib plus spartalizumab versus docetaxel in non-small cell lung cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• DOCETAXEL (DOCETAXEL)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2021-10-25